PMID- 33040170
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20240329
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Print)
IS  - 1534-4827 (Linking)
VI  - 20
IP  - 11
DP  - 2020 Oct 11
TI  - What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
PG  - 63
LID - 10.1007/s11892-020-01347-3 [doi]
LID - 63
AB  - PURPOSE OF REVIEW: We highlight the unique properties of the sodium-glucose 
      cotransporter-2 (SGLT-2 inhibitors) which may lend favorably to their efficient 
      integration in the background of other heart failure (HF) therapies. We also 
      discuss the unique aspects of SGLT-2 inhibitor dosing, lack of titration needs, 
      effects on kidney function and electrolytes, diuretic activity, and safety in the 
      high-risk peri-hospitalization window. RECENT FINDINGS: Dapagliflozin was 
      recently approved for the treatment of heart failure with reduced ejection 
      fraction (HFrEF), irrespective of the presence or absence of type 2 diabetes 
      mellitus (T2DM) based on the findings of the pivotal DAPA-HF trial. All SGLT-2 
      inhibitors are once daily medications with minimal drug-drug interactions and do 
      not require titration (for HF treatment) unlike other HF medications. SGLT-2 
      inhibitors offer modest weight loss and blood pressure reduction without major 
      adverse effects of hyperkalemia, making it ideal for near-simultaneous initiation 
      with other HF medications, and use in high-risk populations (including older 
      adults). Moreover, SGLT-2 inhibitors appear to afford long-term kidney protection 
      in diverse populations. SGLT-2 inhibitors are the latest class of therapies to 
      demonstrate important clinical benefits among patients with HFrEF, and their 
      pharmacological properties favor ease of use and integration in multi-drug 
      disease-modifying regimens.
FAU - Khan, Muhammad Shahzeb
AU  - Khan MS
AD  - Department of Medicine, Cook County Health and Hospital System, Chicago, IL, USA.
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
AD  - Heart and Vascular Center, Brigham and Women's Hospital Heart & Vascular Center 
      and Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA. 
      mvaduganathan@bwh.harvard.edu.
LA  - eng
GR  - UL1 TR002541/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20201011
PL  - United States
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 9NEZ333N27 (Sodium)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Aged
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucose
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - Sodium
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Stroke Volume
PMC - PMC7548057
OTO - NOTNLM
OT  - Antihyperglycemic therapies
OT  - Diabetes mellitus
OT  - Heart failure
OT  - SGLT-2 inhibitors
COIS- Muhammad Shahzeb Khan has no disclosures to report. Muthiah Vaduganathan is 
      supported by the KL2/Catalyst Medical Research Investigator Training award from 
      Harvard Catalyst (NIH/NCATS Award UL 1TR002541); serves on advisory boards for 
      Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, 
      Cytokinetics, and Relypsa; and participates on clinical endpoint committees for 
      studies sponsored by Galmed, Novartis, and the NIH.
EDAT- 2020/10/12 06:00
MHDA- 2021/02/26 06:00
PMCR- 2020/10/11
CRDT- 2020/10/11 20:35
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/10/11 20:35 [entrez]
PHST- 2020/10/12 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
PHST- 2020/10/11 00:00 [pmc-release]
AID - 10.1007/s11892-020-01347-3 [pii]
AID - 1347 [pii]
AID - 10.1007/s11892-020-01347-3 [doi]
PST - epublish
SO  - Curr Diab Rep. 2020 Oct 11;20(11):63. doi: 10.1007/s11892-020-01347-3.